Hematology
Volume 28, 2023 - Issue 1
Open access
1,310
Views
0
CrossRef citations to date
0
Altmetric
Research Article
Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia
Lingling Yina Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China;b Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China;c Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of ChinaView further author information
, Jiawen Xub Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China;c Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of ChinaView further author information
, Wenjian Wud Medical Record and Statistical Office, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaView further author information
, Mingshan Niua Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China;b Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China;c Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of ChinaView further author information
, Zhenyu Lia Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China;b Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China;c Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of ChinaView further author information
, Feng Zhua Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China;b Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China;c Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of ChinaCorrespondence[email protected]
View further author information
& View further author information
Kailin Xua Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China;b Blood Diseases Institute, Xuzhou Medical University, Xuzhou, People’s Republic of China;c Key Laboratory of Bone Marrow Stem Cells, Xuzhou, People’s Republic of ChinaView further author information
show all
Article: 2224625
|
Received 03 Nov 2022, Accepted 22 Apr 2023, Published online: 22 Jun 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.